Drugs / Compound Kushen injection
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05894694 | Sep 2023 → Dec 2025 overdue | colorectal cancer | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Compound Kushen injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05894694 ↗ |
| Known as | CKI | “Compound Kushen injection (CKI) is one of the representative drugs of anti-cancer Chinese herbal injection drugs” PMID 39741233 ↗ Dec 2024 |
| Modality | Traditional medicine (herbal / TCM) | “Compound Kushen injection (CKI) is one of the representative drugs of anti-cancer Chinese herbal injection drugs” PMID 39741233 ↗ Dec 2024 |
| Route | Intravenous | “Compound Kushen injection: intravenous infusion” NCT05894694 ↗ |